Are Compounded GLP-1 Pills Legal in the US?

Compounded GLP-1 pills are not FDA-approved, but they can be legitimate in the U.S. under regulations set by federal and state law. In practice, most “compounded GLP-1 pills” sold today are copies of brand drugs like Ozempic, Wegovy, or Zepbound. These are no longer allowed once the FDA announces the shortage is over.

Here’s what patients and doctors need to know about the legal status, risks, and current rules for compounded GLP-1 pills in 2026.​

What “Compounded GLP-1 Pills” Actually Are

A compounded GLP-1 pill is a personalized oral drug that includes a GLP-1 receptor agonist (like semaglutide or tirzepatide) mixed into a pill by a licensed pharmacy. These are not the same as FDA-approved pills like Rybelsus (oral semaglutide) or the new daily Wegovy pill.

Compounded pills are made when a patient cannot use the commercial product for a specific medical reason. For example, a patient might need:

• A dosage different from what’s commercially available.
• A composition without a certain dye, preservative, or filler to which they’re allergic.
• A liquid or capsule form, because they cannot swallow tablets.

When a compounded pill is just a cheaper copy of an FDA-approved GLP-1 drug, it is considered “essentially a copy” and is not permitted once the shortage ends.

How U.S. Law Treats Compounded Drugs

According to the Federal Food, Drug, and Cosmetic Act, compounded drugs are treated differently from FDA-approved brand and generic drugs. The key points are:​

• Compounded drugs are not FDA-approved.
• The FDA does not review them for safety, effectiveness, or quality before they are sold.
• They are allowed only when an FDA-approved drug won’t work for a specific patient.
  • For example, if a patient is allergic to a component in the brand product, a compounded version without that ingredient may be appropriate.
• They cannot be “essentially a copy” of a commercially available FDA-approved drug.
  • Once the FDA determines that a drug is no longer in shortage, compounding exact copies is no longer allowed under federal law.
• They must be made by a licensed pharmacist in a state-licensed pharmacy or an FDA-registered outsourcing facility.
  • These facilities must follow state and federal rules on compounding practices and labeling.

The GLP-1 Shortage and Why It Matters

From 2022 through early 2025, there was a countrywide shortage of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). During that time, the FDA permitted compounding pharmacies to manufacture injectable versions of these drugs as a temporary step.

In 2025, the FDA announced that the shortage of semaglutide and tirzepatide injections had been resolved. That meant:

• State-licensed pharmacies and physicians could no longer lawfully compound copies of these drugs under section 503A.
• Outsourcing facilities (503B) had a short grace period, but that has now expired.

For compounded GLP-1 pills, the same rule applies: if a patient can be managed with an FDA-approved oral GLP-1 (like Rybelsus or the new Wegovy pill), a compounded pill that is just a copy is not permitted.

When Compounded GLP-1 Pills Are Still Legal

Compounded GLP-1 pills can still be legal in the U.S. in a few narrow situations. These include:

• The patient has a documented medical need that the FDA-approved product cannot meet.
  • For example, a severe allergy to an excipient in the brand pill, or a swallowing disorder that requires a liquid or capsule form.
• The compounded product includes a change that makes a “significant difference” for that patient.
  • This could be a different strength, a different salt form (if appropriate), or a combination with another medication that is not commercially available.
• The drug is not commercially available in the needed form or strength.
  • If no FDA-approved oral GLP-1 is available in the exact dose or formulation the patient needs, compounding may still be allowed.
• The compounding is done by a licensed pharmacy or outsourcing facility following state and federal rules.
  • The pharmacy must be licensed, and the product must be labeled correctly with strength, expiration, and storage instructions.

Outside of these situations, most compounded GLP-1 pills are considered illegal “copies” of approved drugs and are not permitted under current FDA policy.

Risks of Using Compounded GLP-1 Pills

Even when legally compounded, GLP-1 pills carry more risk than FDA-approved products. Key concerns include:

• No FDA pre-market review. The FDA does not verify that the compounded pill is safe, effective, or consistently made before it reaches patients.
• Quality and strength issues. Some compounded products have been found to contain too much or too little active ingredient, or to be contaminated.
• Dosing errors. Patients and prescribers may miscalculate doses, especially with vials or multi-dose bottles, leading to serious side effects like nausea, vomiting, or hospitalization.
• Use of unapproved salt forms. Some compounders use semaglutide sodium or semaglutide acetate, which are different from the active ingredient in approved drugs and have not been evaluated for safety or effectiveness.
• Fraudulent or counterfeit products. The FDA has warned about fraudulent compounded GLP-1 drugs with fake labels, non-existent pharmacies, or products sold as “for research only” but used for human weight loss.

Because of these risks, the American Diabetes Association and many medical groups recommend using FDA-approved GLP-1 drugs whenever possible.

How to Tell If a Compounded GLP-1 Pill Is Legal and Safe

Patients and prescribers can take several steps to ensure they are using a legal, higher-quality compounded GLP-1 pill:

• Confirm that an FDA-approved product cannot meet the patient’s needs.
  • If a commercial oral GLP-1 (like Rybelsus or the new Wegovy pill) is appropriate, that should be used instead.
• Require a clear, documented medical reason for compounding.
  • The prescription should state why the compounded product is necessary (e.g., allergy, swallowing difficulty, specific strength).
• Use only a licensed U.S. pharmacy or FDA-registered outsourcing facility.
  • Avoid online clinics or pharmacies that do not clearly identify the compounding pharmacy or that operate outside the U.S.
• Check the label and ingredients.
  • The label should list the active ingredient (e.g., semaglutide), strength, expiration date, and storage instructions.
  • Be cautious of products labeled with salt forms (semaglutide sodium, semaglutide acetate) or “for research only.”
• Discuss risks and monitoring with the prescriber.
  • Ask about how the dose will be calculated, how side effects will be monitored, and what to do if problems arise.

Legal Status of Compounded GLP-1 Pills in 2026: Quick Summary

Situation	Is It Legal?	Key Conditions
Patient needs a different strength or formulation not available in FDA-approved oral GLP-1 drugs	Yes, potentially	Must be for an identified patient with a documented medical need; not an “essentially a copy” ​
Patient is allergic to an ingredient in the FDA-approved pill	Yes, potentially	Change must produce a “significant difference” for that patient, documented by the prescriber ​
A compounded pill is just a cheaper copy of Wegovy, Ozempic, or Zepbound	No	Once the shortage is resolved, compounding “essentially a copy” is not permitted ​
The product is sold online as “for research only” or “not for human use”	No	These are illegal if marketed or used for human weight loss ​
The product is made by an unlicensed or foreign facility	No	Only state-licensed pharmacies and FDA-registered outsourcing facilities may legally compound ​

Conclusion

Compounded GLP-1 pills are not FDA-approved and are only legal in the U.S. when they meet rigid federal and state conditions. In 2026, most “compounded GLP-1 pills” sold as affordable alternatives to branded drugs are not permitted once the FDA has declared the shortage over.

For patients, the safest approach is to:

• Use FDA-approved oral GLP-1 drugs (like Rybelsus or the new Wegovy pill) when possible.
• Only consider a compounded pill if there is a clear, documented medical reason that the approved product cannot be used.
• Work with a licensed prescriber and a reputable U.S. pharmacy, and ask questions about the product’s ingredients, strength, and risks.

For prescribers and pharmacies, compliance means:

• Avoiding compounding essentially a copy of commercially available GLP-1 drugs.
• Documenting the specific patient need and the “significant difference” the compounded product provides.
• Following FDA and state rules on compounding, labeling, and quality standards.

If in doubt, consult current FDA guidance and state pharmacy board rules before prescribing or dispensing any compounded GLP-1 product.